PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biochemistry. Author manuscript; available in PMC 2008 December 8.
Published in final edited form as:
PMCID: PMC2597485
NIHMSID: NIHMS61130

Deducing the transmembrane domain organization of presenilin-1 in γ-secretase by cysteine disulfide crosslinking

Abstract

γ-Secretase is a founding member of membrane-embedded aspartyl proteases that cleave substrates within transmembrane domains, and this enzyme is an important target for the development of therapeutics for Alzheimer’s disease. The structure of γ-secretase and its precise catalytic mechanism still remain largely unknown. γ-Secretase is a complex of four integral membrane proteins, with presenilin (PS) as the catalytic component. To gain structural and functional information about the 9-transmembrane domain (TMD) presenilin, we employed a cysteine mutagenesis/disulfide-crosslinking approach. Here we report that native Cys92 is close to both Cys410 and Cys419, strongly implying that TMD1 and TMD8 are adjacent to each other. This structural arrangement also suggests that TMD8 is distorted from an ideal helix. Importantly, binding of an active-site directed inhibitor, but not a docking-site directed inhibitor, reduces the ability of the native cysteine pairs of PS1 to crosslink upon oxidation. These findings suggest that the conserved cysteines of TMD1 and TMD8 contribute to or allosterically interact with the active site of γ-secretase.

Accumulation of the amyloid β-protein (Aβ) is one of the defining pathological features of Alzheimer’s disease. Aβ is produced from the amyloid β-protein precursor (APP) as a result of sequential proteolytic cleavages first by β-secretase (1) and then by γ-secretase (2). γ-Secretase is an aspartyl transmembrane protease that cleaves a number of type I membrane protein substrates, including APP and Notch, in the middle of their transmembrane domains in a poorly understood process of hydrolysis within a hydrophobic environment (3). γ-Secretase is composed of four transmembrane proteins, Aph-1, Pen-2, Nicastrin (NCT) (410) and presenilin (PS), which is ostensibly the catalytic component of an unusual aspartyl protease (3, 11, 12). Despite substantial progress in establishing the full identity of γ-secretase (79, 13, 14) and the step-wise assembly of the γ-secretase complex (7, 15, 16), the molecular structure of the protease complex or even any of its individual components remains unknown. PS, as the catalytic component, is of major interest, but only some indirect evidence about its structural arrangement has been reported to date. Indeed, it has only very recently been established that PS1 is a 9-TMD protein (17, 18). PS is endoproteolytically processed into an N-terminal fragment (NTF) and C-terminal fragment (CTF) (19). These fragments are metabolically stable, remain associated, and their formation is tightly regulated (20). Also, it is widely accepted, although not definitively proven, that the conserved aspartates D257 and D385 of presenilin constitute a catalytic dyad, and therefore these residues are expected to be proximal (21). This view implies that TMD6 and TMD7 of PS-1 should be directly adjacent to one another. Studies by Annaert et al provided evidence for a proposed “ring structure” for PS1, in which TMD1 is proximal to the C-terminus of the protein (22). Additionally, we have recently reported evidence that residue L166 in TMD3 may be a part of the active site, proposing that TMD3 is possibly in proximity to TMD6 and TMD7 (23). Finally, a report by Brunkan et al (24) provided evidence suggesting that TMD1 contributes to the active site.

An understanding of the mechanism of γ-secretase proteolysis requires a detailed description of the three-dimensional organization of its transmembrane domains. In light of inherent difficulties in obtaining a structure of γ-secretase using methods such NMR spectroscopy, x-ray or electron diffraction, it is crucial to explore alternative approaches that would allow the determination of transmembrane domain organization and offer hints to how familial Alzheimer-causing mutations in PS, which are scattered along the whole sequence of the protein, cause essentially the same effect on APP processing (increasing the proportion of 42-residue Aβ to its 40-residue form). One very promising strategy, which surprisingly has not been reported in the study of γ-secretase, is cysteine mutagenesis/disulfide crosslinking. This method involves the introduction of cysteine residues at specific positions within transmembrane domains by site-directed mutagenesis and subsequent use of chemical reactivity of the introduced sulfhydryl groups. Because transmembrane cysteines are typically not accessible to modifying reagents, the most commonly used approach is cysteine-cysteine disulfide crosslinking, in which an oxidizing agent is used to catalyze the formation of disulfide bonds between proximal transmembrane cysteines and yield unique high-molecular weight products. This approach has been widely applied to deduce the oligomeric state of transmembrane proteins (25, 26), the identification of transmembrane domain organization (2730), identification of contact points within the protein (31) and even accessing the mechanistic details of drug and substrate interaction with transmembrane targets (32).

Here, we report findings about the PS structure obtained by utilizing the powerful approach of cysteine mutagenesis/disulfide crosslinking. To provide direct biochemical evidence for the arrangement of transmembrane domains in presenilin and to establish the means of probing its structure and mechanism, we initiated studies involving oxidative disulfide crosslinking of PS1.

EXPERIMENTAL PROCEDURES

Plasmids, Mutagenesis

Site-directed mutagenesis was performed with the Stratagene Multi-Site QuickChange mutagenesis kit. Mutations were introduced into plasmid pcDNA3.1 (Invitrogen) containing PS1 with a Flag epitope on the N-terminus (8). Mutations were confirmed by DNA sequence analysis.

Transfections and stable cell line generation

We used PS1/PS2 KO ES blastocyst mouse cells, which we obtained as a gift from B. Yankner (Harvard Medical School). ES cells were grown in DMEM supplemented with 15% FBS, non-essential amino acids, penicillin/streptomycin, sodium pyruvate, L-glutamine, 0.01% leukemia inhibitory factor (“ESGRO”, Chemicon), and 2-mercaptoethanol (100 µM). Six-well plates of ES cells at 60–70% confluence were transfected with 2 µg of corresponding cDNA and with 6 µL of Lipofectamine (Invitrogen) and 500 µL of OPTIMEM (Invitrogen). Six hours after transfection, 500 µL of ES media was added. Twenty-four hours after transfection, the cells were replated at 12–25% into six-well plates and 40 µg/ml zeocin was added to select for a stably transfected pool of cells. Single colonies were generated by replating the cells from the pool into 96-well plates at 1.2 cells/well. The protein expression level was analyzed by Western Blotting and the best expressing cell colonies were picked.

Preparation of microsomes

ES cells (stably expressing the appropriate PS1 construct) or HeLa cells (expressing endogenous PS1) were grown, washed with PBS and homogenized in Buffer A (10 mM HEPES, pH 7.4, 1 mM EDTA, 0.25 M sucrose, and protease inhibitors (Roche)). The cell homogenate was centrifuged at 20,000g, and the supernatant was spun at 100,000g and 4°C for 1 hr to pellet the membranes. The membranes were suspended in HEPES buffer (50 mM HEPES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2) containing 1% CHAPSO and incubated for 1 hr at 4°C. The final suspension was spun at 100,000 g at 4°C for 1 hr to isolate the solubilized membranes.

Disulfide crosslinking

Solubilized membranes were diluted to a final concentration of 0.25% CHAPSO by addition of HEPES buffer. For oxidation, 15 µl of this suspension was mixed with 0.5 µL of 30 mM Cu2+(phenanthroline) (Cu2+Phe) (30 mM CuSO4, 90 mM 1,10-phenanthroline in 50 mM PBS, pH 7.3) and incubated at 37 °C for 30 min. To stop the reaction, 4 µL of 4x Laemmli sample buffer (containing no β-mercaptoethanol, but 100 mM EDTA and 100 mM NEM (N-ethylmaleimide). The samples were subjected to non-reducing SDS-PAGE and analyzed by immunoblotting.

Reduction of Crosslinked Products

100 mM EDTA was added to oxidized samples before addition of the reducing agents. Oxidized species were reduced in the presence of 1% SDS either with 100 mM β-mercaptoethanol (βME) at pH 6.8 or with 100 mM dithiothreitol (DTT) at pH 9.0 and 60 °C for 30 min.

The effect of inhibitors on PS1 oxidation

HeLa cell solubilized membranes were oxidized with Cu2+Phe in the presence of corresponding amounts of γ-secretase inhibitors. The inhibitors were added to the samples and incubated for 20 min prior to addition of oxidizing agent.

Compounds and antibodies

The syntheses of III-31-C, D-10, and D-13 were accomplished as previously reported (10, 33, 34). Compound E (35) was synthesized according to published procedures. All compounds were HPLC purified and analyzed by MALDI-TOF and dissolved in DMSO to make stock solutions. The following antibodies were used for immunoblotting: 231-f (a-PS1-NTF, polyclonal raised to amino acids 2–20, from B. Yankner), 4627 (a-PS1-CTF, polyclonal raised to amino acids 457–467 of PS1, from Elan), MAB5232 (a-PS1-CTF, monoclonal raised to amino acids 263–378, Chemicon), UD-1 (a-Pen2, polyclonal raised to N-terminal residues ERVSNEEKLNL, from J. Naslund), Aph1 antibody (polyclonal, Zymed).

RESULTS

WT-PS1 undergoes oxidative disulfide crosslinking

To test whether wt-PS1 undergoes crosslinking in the presence of oxidizing agents, we incubated CHAPSO-solubilized endogenous γ-secretase isolated from HeLa cells (36) with copper phenanthroline (Cu2+Phe), a potent oxidizing agent known to induce disulfide bond formation not only between water exposed cysteines, but even between transmembrane cysteines (2527, 30). We observed a decrease in the level of PS1-NTF and the rise of a newly formed ~45–50 kDa product, a size corresponding to PS1-NTF/PS1-CTF (Fig. 1A). We also detected a smaller amount of a newly formed species of ~35–37 kDa, which was cross-reactive with anti-PS1-NTF antibodies. To establish the identity of the oxidation products, we probed them with two different PS1-CTF antibodies. One CTF antibody (MAB5232) clearly indicated the decrease in PS1-CTF levels and the appearance of a new ~45–50 kDa species (Fig. 1A, second panel). Another antibody (4627, raised against C-terminus of PS1-CTF), which is less sensitive than MAB5232, but able to detect a caspase-cut 10 kDa alternative PS1-CTF (PS1-alt-CTF) (37, 38), detected decreases in levels of both CTF and a putative PS1-alt-CTF upon Cu2+Phe oxidation (Fig 1a, third panel). The latter antibody was less sensitive and did not cross-react with ~45–50 kDa or ~35–37 kDa species. These results altogether suggest that the observed ~45–50 kDa oxidation product corresponds to NTF being crosslinked to CTF. Reduction in the putative alt-CTF level was noted (Fig 1a, third panel) along with the appearance of the 35–37 kDa product (first panel), suggesting that the identity of the latter could be NTF crosslinked to alt-CTF. However, while the identity of the 10 kDa band as PS1 alt-CTF is consistent with previously reports (37, 38), we cannot say with certainty that it is not another protein with some crossreactivity to the PS1 C-terminal antibody. Neither is it certain that the ~35–37 kDa oxidation product corresponds to NTF crosslinked to alt-CTF, because this product was only detected with anti-NTF antibody. Attempts to increase levels of the putative alt-CTF and the crosslinked NTF-alt-CTF using staurosporine gave equivocal results. Levels of Pen-2 and Aph-1 did not change upon oxidation, ruling out the possibility of ~45–50 kDa product being NTF-Aph1 and 35–37 kDa product being NTF-Pen-2.

Figure 1
Disulfide oxidation of endogenous PS1

Importantly, when 1% NP-40 and 1% SDS were added to the samples before oxidation, reduced levels (in NP-40 sample) and virtually no oxidized products (in SDS sample) were detected (Fig. 1B). NP-40 and SDS detergents are known to dissociate γ-secretase complex and to partially unfold transmembrane proteins (10). Therefore, this observation indicates that formation of oxidized wt-PS1 products is specific; that is, they are formed only when PS1 is a part of the assembled γ-secretase complex.

Disulfide bonds are often easily reduced in the presence of excess of thiol reductant, such as βME and DTT, and SDS. Treatment of the oxidized PS1 products with 100 mM βME (pH 6.8) or with 100 mM DTT (pH 9.0) at 60 °C for 20 min resulted in a partial conversion of the crosslinked NTF-CTF back to NTF and CTF (Fig. 1C). Incubation at higher temperature (90 °C) could have improved the conversion efficiency; however, PS1 aggregates at temperatures higher than 60–65 °C (data not shown). Nevertheless, the reducing conversion, although not complete, provides evidence that the PS1 crosslinked products are due to disulfide bond formation.

Our results together indicate that wt-PS1-NTF and wt-PS1-CTF can be crosslinked as a result of disulfide bond formation between proximal cysteines upon oxidation. Therefore, this finding strongly suggests that there are at least 2 native cysteine residues in the PS1 sequence, one in the NTF and one in the CTF, that are in close proximity (< 7 Å). Because some evidence suggests that the γ-secretase complex may contain two PS1 molecules (39, 40), it is possible that the crosslinked NTF-CTF is derived from two different PS1 molecules (i.e., crosslinking in trans). To address this issue, we generated PS1 KO ES cells stably expressing the PS1 ΔE9 mutant (with an N-terminal Flag epitope). This mutant causes Alzheimer’s disease and supports γ-secretase activity; however, because the deleted exon 9 encodes the site of PS1 endoproteolysis, this PS1 variant does not form NTF or CTF (19, 41). When solubilized membranes from these cells were subjected to crosslinking, the PS1 ΔE9 band migrated slightly faster (Fig. 1D), perhaps due to internal crosslinking within a single PS1 molecule. No sign of dimeric PS1 ΔE9 was seen, suggesting that cysteine crosslinking between NTF and CTF in wt PS1 does not occur in trans.

Disulfide oxidation of C92S, C410S and C419S PS1 mutants

To establish which native cysteines of PS1 are proximal, we employed site-directed mutagenesis. Human PS1 contains 5 native cysteines. According to currently accepted PS1 topology (17, 18), 3 cysteines are in transmembrane domains and 2 are exposed to cytosol (Fig. 2A). Importantly, all 3 transmembrane cysteines are well-conserved (Fig. 2B) and Cys92 and Cys410 are sites of FAD mutations (42, 43). Only two of these native cysteines, Cys410 and Cys419, are in the PS1-CTF, and both are located in TMD8. Because the observed product of crosslinking in the γ-secretase complex corresponds to NTF-CTF, apparently either Cys410 or Cys419 forms a disulfide bond with the only other transmembrane Cys92, which is located in TMD1 of PS1-NTF. We aimed to determine which of these pairs are responsible for native PS1 crosslinking and to elucidate whether TMD1 and TMD8 are adjacent to each other.

Figure 2
Topological model of PS1 and location of its native cysteines

We generated point mutants C92S, C410S and C419S of PS1-Flag and raised PS1/PS2 KO ES cells stably expressing each of these mutants. All mutants underwent efficient endoproteolysis (19), as indicated by the lack of full-length PS1 (FL-PS1, 50 kDa), suggesting that neither mutation affected PS1 participation in active γ-secretase assembly (Fig. 3B and C, non-oxidized samples). In addition, for all mutants we observed efficient co-immunoprecipitation of PS1-CTF with Flag-tagged PS1-NTF using M2-beads (anti-Flag), confirming that these PS1 mutations do not interfere with the ability of PS1 to form γ-secretase complexes (Fig. 3A). Upon oxidation with Cu2+Phe, only the C92S-PS1 mutant yielded neither the oxidation product nor the decrease in PS1-NTF level, suggesting that Cys92 (located in PS1-NTF) is responsible for wt-PS1-NTF disulfide crosslinking to wtPS1-CTF (Fig. 3B). Surprisingly, both the C410S and C419S PS1 mutants were oxidized similarly to wt-PS1, producing a product corresponding to NTF-CTF (Fig. 3C), which suggests that either of these cysteines can contribute to wt-NTF-CTF formation and either one can crosslink to Cys92.

Figure 3
Disulfide oxidation of PS1 mutants

Disulfide oxidation of a C410S/C419S PS1 double mutant

To clarify the role of Cys410 and Cys419 in wt-PS1 crosslinking, we prepared a double mutant C410S/C419S-PS1 (abbreviated as “C410/419S”) and generated an ES cell line stably expressing this mutant. Notably, unlike in C92S, C410S and C419S single mutants, a residual amount of FL-PS1 was observed with the C410/419S-PS1 mutant, although most of the PS1 double mutant did get endoproteolized into NTF and CTF (Fig. 3D). In addition, we observed efficient co-immunoprecipitation of PS1-CTF with Flag-tagged PS1-NTF using M2-beads (anti-Flag), confirming that these double PS1 mutations do not interfere with the ability of PS1 to form γ-secretase complexes (Fig. 3A). Upon oxidation of C410/419S–PS1, we observed no substantial decrease in levels of PS1-NTF and PS1-CTF and no increase in level of FL-PS1 (Fig. 3D), indicating that a cysteine-less CTF loses its ability to disulfide crosslink to PS1-NTF. Together with the findings discussed above, these data suggest that Cys92 can crosslink to either Cys410 or Cys419 to yield NTF-CTF crosslinked species. Cys410 and Cys419 are separated by 9 amino acids and are expected to be located on almost opposite sides of the same transmembrane helix. Therefore, the proximity arrangement intriguingly implies that TMD8 must have a kink in its helical structure in order for both Cys410 and Cys419 to be able to crosslink to Cys92.

Effect of γ-secretase inhibitor binding on wt-PS1 oxidative crosslinking

Because cysteines are required to be in proximity of less that 7 Å in order for a disulfide bond to be formed (44), disulfide crosslinking provides a sensitive method to assess conformational changes in protein structure, whether due to ligand or inhibitor binding or some other event. We analyzed the ability of known γ-secretase inhibitors to affect the oxidative disulfide crosslinking of wt-PS1. Besides active-site directed transition-state analogue inhibitor III-31-C (10), we also analyzed non-transition-state analogue Compound E (35) as well as helical peptides D-10 and D-13, which are docking site directed inhibitors (23, 33). Compounds were added to the samples just before addition of Cu2+Phe oxidant, and after 30 min incubation at 37 °C, the samples were analyzed by SDS-PAGE. Remarkably, active-site directed inhibitor III-31-C completely prevented NTF from crosslinking, as almost no oxidized products were detected and NTF level did not change (Fig. 4). In contrast, docking-site directed D-10 helical peptide inhibitor did not affect the formation of crosslinked NTF-CTF. Similar behavior was observed when III-31-C and D-10 were incubated with C410S and C419S PS1 mutants (data not shown). Different effects of III-31-C and D-10 on PS1-NTF-CTF crosslinking independently support our previous findings that III-31-C and D-10 inhibitors bind PS1 at distinct sites, active site and docking site, respectively (23, 45). Compound E and D-13 exhibited an intermediate behavior, as these inhibitors prevented NTF-CTF disulfide crosslinking, but not as efficiently as the transition-state analogue (Fig. 4). This is consistent with our previous findings that Compound E and D-13 bind PS1 in a mode partial overlapping with the active site of γ-secretase (23, 45). Most importantly, the ability of the active-site directed III-31-C to interfere with PS1 oxidative crosslinking suggests that native Cys92, Cys410 and/or Cys419 are close to or within the active site of γ-secretase with the inhibitor binding preventing their interaction, or that the occupation of the active site results in a substantial conformational change in the PS1 molecule which in turn translates into a shift in distance between cysteine pairs.

Figure 4
Transition–state analogue inhibitor III-31-C, but not the helical peptide inhibitor D-10, prevents disulfide oxidation of the endogenous PS1

DISCUSSION

γ-secretase is one of the most important targets in the development of therapeutics for Alzheimer’s Disease as well as in understanding how mutations in PS1 that cause familial Alzheimer’s disease (FAD) shift the Aβ production towards the more aggregation-prone Aβ42 peptide. In order to understand this target, it is crucial to obtain information about its active site organization and the role of FAD residues. Unfortunately, γ-secretase is a difficult protein to study structurally using standard techniques, as it consists of four transmembrane proteins with a total of at least 19 transmembrane domains (an exact protein stoichiometry is still unknown), and it is difficult to express recombinantly. Alternative methods such as disulfide crosslinking should be used to gain structural information about this enigmatic protease. To this end, we initiated the application of cysteine oxidation towards γ-secretase and found that wt-PS1-NTF and wt-PS1- CTF crosslink to each other as a result of disulfide bond formation between native cysteines. Treatment of detergent-solubilized endogenous γ-secretase with Cu2+Phe oxidant results in the formation of PS1-NTF-CTF. This observation, together with the control reactions, strongly suggests that at least two native cysteines in PS1 are in proximity. These native transmembrane cysteines in PS1 and the disulfide crosslinked products exhibit some interesting properties. The newly formed disulfides bonds are extremely stable towards reducing agents. A lack of reactivity is not uncommon for transmembrane cysteines and is considered to be due to a high pKa of sulfhydryl in the hydrophobic environment. Thus, in aspartate receptors the disulfides are very stable on exposure to low molecular weight thiols, such as DTT and βME, in the presence of SDS and require extreme pH and heat for reduction (27).

By employing site-directed mutagenesis, we have determined that highly conserved transmembrane Cys92 in PS1-NTF and Cys410 and Cys419 of CTF are responsible for crosslinking between wt-PS1-NTF and wt-PS1-CTF. Our findings suggest that both Cys410 and Cys419 can crosslink to Cys92. It has been shown that α-carbons of the cross-linked cysteines can be at a maximum distance of 7 Å from each other, with an average of 5–6 Å (44). Obviously, the cysteines have to be on facing sides of the two helices for the disulfide bond to form (27). Therefore, our data clearly indicate that TMD1 and TMD8 of PS1 are in close proximity. Cys92 in TMD1 is located close to both Cys410 and Cys419 in TMD8. Because Cys410 and Cys419 are separated by 9 amino acids, it is puzzling how Cys92 can be close to both of them. This finding raises an intriguing question about the microstructure of TMD8. Presumably, a break in a TMD8 α-helix, such as a kink or a loop can bring Cys410 and Cys419 closer to each other and Cys92. This “imperfection” in a helix would be consistent with the fact that TMD8 has one of the longest (≥20-residue) hydrophobic stretches in PS1, and more importantly, that TMD8 has a completely conserved Gly417 residue in a middle of its sequence. Glycine is known to be a transmembrane helix breaker or a hinge, as has been shown in the structure of Shaker potassium channel (46). Overall, our observations provide biochemical evidence for more detailed structural information about the catalytic component of γ-secretase.

Besides providing a better idea of the organization of PS1 TMDs, disulfide crosslinking offered the means to probe changes in PS1 upon inhibitor binding. Thus, we discovered that binding of transition-state analogue inhibitor III-31-C prevents PS1-NTF and PS1-CTF disulfide crosslinking. In contrast, binding of docking-site directed inhibitor D-10 does not interfere with oxidized product formation. These observations confirm our initial findings that there are two distinct sites on γ-secretase and that III-31-C and D-10 inhibitors bind to the active-site and the docking site, respectively (10, 23, 45). The ability of III-31-C to affect wt-PS1-NTF and wt-PS1-CTF disulfide-crosslinking suggests that its binding decreases the proximity of cysteines involved in crosslinking. Such alteration can be induced by either a conformational change of PS1 upon inhibitor binding or by active-site directed III-31-C binding directly in proximity to the interacting cysteines. Intriguingly, the latter possibility would indicate that Cys92, Cys410 or Cys419 are located in the active site cavity. In fact, this arrangement is supported by the previously reported finding implicating TMD1, in which Cys92 is located, as part of the active site (24). The sophisticated arrangement of three highly conserved cysteines along with the helix breaking Gly417 suggests that these residues may be crucial for the protease activity and play a major role in its active site. As a result, we believe our findings imply that Cys92, Cys410 or Cys419 are located near or are allosterically interacting with the active site of γ-secretase, suggesting that these highly conserved cysteines may have a function in supporting the integrity and hydrophilic environment of the internal active site.

In summary, we have initiated the use of the powerful method of disulfide crosslinking towards probing the three-dimensional structure of γ-secretase. Our observations provide new structural information about the TMD organization of PS1, the catalytic component of gamma-secretase. The disulfide crosslinking method may eventually reveal additional structural details about the gamma-secretase complex. By incorporating cysteine residues into a cysteine-free PS1 and analyzing the ability to form disulfide crosslinks, the complete organization of the TMDs of PS1 and that of its active site could be ultimately determined, and the location within PS1 of contacts with other gamma-secretase components could be elucidated as well. These findings will provide important validation in the future, when the long-awaited crystal structure of γ-secretase is finally solved.

ACKNOWLEDGMENT

We thank Bruce Yankner for PS1/PS2 KO ES cells and 231-f antibody, J. Näslund for UD-1 antibody, S. Urban for helpful comments on the manuscript, M. Leissring, J. Fadeeva and S. Urban for the advice in molecular biology.

Footnotes

This work was supported by grants to M.S.W. from the National Institutes of Health (NS41355 and AG17574) and the Alzheimer’s Association (IIRG-02-4047) and a fellowship to H. L. (Wenner-Gren Foundation in Sweden).

1Abbreviations: PS1, presenilin 1; NTF and CTF, N- and C-terminal fragments; TMD, transmembrane domain; ES, embryonic cells; KO, knock-out; DMEM, Dulbecco’s Modified Eagle’s Medium; PBS, Phosphate Buffered Saline; Cu2+Phe, Cu2+(phenanthroline); NEM, Nethylmaleimide; βME, β-mercaptoethanol; DTT, dithiothreitol.

REFERENCES

1. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. Science. 1999;286:735–741. [PubMed]
2. Wolfe MS, Selkoe DJ. Intramembrane proteases--mixing oil and water. Science. 2002;296:2156–2157. [PubMed]
3. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science. 2004;305:1119–1123. [PubMed]
4. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song YQ, Rogaeva E, Chen F, Kawarai T, Supala A, Levesque L, Yu H, Yang DS, Holmes E, Milman P, Liang Y, Zhang DM, Xu DH, Sato C, Rogaev E, Smith M, Janus C, Zhang Y, Aebersold R, Farrer LS, Sorbi S, Bruni A, Fraser P, St George-Hyslop P. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407:48–54. [PubMed]
5. Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A. 2002;99:775–779. [PubMed]
6. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li J, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS, Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3:85–97. [PubMed]
7. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438–441. [PubMed]
8. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proc Natl Acad Sci U S A. 2003;100:6382–6387. [PubMed]
9. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486–488. [PubMed]
10. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. Activity-dependent isolation of the presenilin/γ-secretase complex reveals nicastrin and a γ substrate. Proc Natl Acad Sci U.S.A. 2002;99:2720–2725. [PubMed]
11. Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science. 2001;293:1449–1454. [PubMed]
12. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9–12. [PubMed]
13. Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, Van Dorsselaer A, Wang R, Selkoe DJ, Wolfe MS. Purification and Characterization of the Human gamma-Secretase Complex. Biochemistry. 2004;43:9774–9789. [PubMed]
14. Hayashi I, Urano Y, Fukuda R, Isoo N, Kodama T, Hamakubo T, Tomita T, Iwatsubo T. Selective reconstitution and recovery of functional gamma-secretase complex on budded baculovirus particles. J Biol Chem. 2004;279:38040–38046. [PubMed]
15. Hu Y, Fortini ME. Different cofactor activities in gamma-secretase assembly: evidence for a nicastrin-Aph-1 subcomplex. J Cell Biol. 2003;161:685–690. [PMC free article] [PubMed]
16. LaVoie MJ, Fraering PC, Ostaszewski BL, Ye W, Kimberly WT, Wolfe MS, Selkoe DJ. Assembly of the {gamma}-Secretase Complex Involves Early Formation of an Intermediate Subcomplex of Aph-1 and Nicastrin. J Biol Chem. 2003;278:37213–37222. [PubMed]
17. Laudon H, Hansson EM, Melen K, Bergman A, Farmery MR, Winblad B, Lendahl U, von Heijne G, Naslund J. A nine transmembrane domain topology for presenilin 1. J Biol Chem. 2005;25:25. [PubMed]
18. Oh YS, Turner RJ. Topology of the C-terminal fragment of human presenilin 1. Biochemistry. 2005;44:11821–11828. [PubMed]
19. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181–190. [PubMed]
20. Wolfe MS, Haass C. The Role of Presenilins in gamma-Secretase Activity. J Biol Chem. 2001;276:5413–5416. [PubMed]
21. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 1999;398:513–517. [PubMed]
22. Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron. 2001;32:579–589. [PubMed]
23. Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc Natl Acad Sci U S A. 2005;102:3230–3235. [PubMed]
24. Brunkan AL, Martinez M, Wang J, Walker ES, Beher D, Shearman MS, Goate AM. Two domains within the first putative transmembrane domain of presenilin 1 differentially influence presenilinase and gamma-secretase activity. J Neurochem. 2005;94:1315–1328. [PubMed]
25. Bunn MW, Ordal GW. Transmembrane organization of the Bacillus subtilis chemoreceptor McpB deduced by cysteine disulfide crosslinking. J Mol Biol. 2003;331:941–949. [PubMed]
26. Hastrup H, Sen N, Javitch JA. The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs. J Biol Chem. 2003;278:45045–45048. [PubMed]
27. Lynch BA, Koshland DE., Jr Disulfide cross-linking studies of the transmembrane regions of the aspartate sensory receptor of Escherichia coli. Proc Natl Acad Sci U S A. 1991;88:10402–10406. [PubMed]
28. Pakula AA, Simon MI. Determination of transmembrane protein structure by disulfide cross-linking: the Escherichia coli Tar receptor. Proc Natl Acad Sci U S A. 1992;89:4144–4148. [PubMed]
29. Lee GF, Burrows GG, Lebert MR, Dutton DP, Hazelbauer GL. Deducing the organization of a transmembrane domain by disulfide cross-linking. The bacterial chemoreceptor Trg. J Biol Chem. 1994;269:29920–29927. [PubMed]
30. Loo TW, Bartlett MC, Clarke DM. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. J Biol Chem. 2004;279:7692–7697. [PubMed]
31. Soskine M, Steiner-Mordoch S, Schuldiner S. Crosslinking of membrane-embedded cysteines reveals contact points in the EmrE oligomer. Proc Natl Acad Sci U S A. 2002;99:12043–12048. [PubMed]
32. Loo TW, Bartlett MC, Clarke DM. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem. 2003;278:39706–39710. [PubMed]
33. Das C, Berezovska O, Diehl TS, Genet C, Buldyrev I, Tsai JY, Hyman BT, Wolfe MS. Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc. 2003;125:11794–11795. [PubMed]
34. Bihel F, Das C, Bowman MJ, Wolfe MS. Discovery of a subnanomolar helical D-tridecapeptide inhibitor of γ-secretase. J Med Chem. 2004;47:3931–3933. [PubMed]
35. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R. Presenilin-1 and -2 are molecular targets for gamma -secretase inhibitors. J Biol Chem. 2000;275:34086–34091. [PubMed]
36. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Presenilin 1 is linked with gamma -secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000;97:6138–6143. [PubMed]
37. Loetscher H, Deuschle U, Brockhaus M, Reinhardt D, Nelboeck P, Mous J, Grunberg J, Haass C, Jacobsen H. Presenilins are processed by caspase-type proteases. J Biol Chem. 1997;272:20655–20659. [PubMed]
38. Grunberg J, Walter J, Loetscher H, Deuschle U, Jacobsen H, Haass C. Alzheimer's disease associated presenilin-1 holoprotein and its 18–20 kDa C-terminal fragment are death substrates for proteases of the caspase family. Biochemistry. 1998;37:2263–2270. [PubMed]
39. Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M, Kopan R. A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A. 2003;100:13075–13080. [PubMed]
40. Cervantes S, Saura CA, Pomares E, Gonzalez-Duarte R, Marfany G. Functional implications of the presenilin dimerization. Reconstitution of gamma - secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins. J Biol Chem. 2004;25:25. [PubMed]
41. Steiner H, Romig H, Grim MG, Philipp U, Pesold B, Citron M, Baumeister R, Haass C. The biological and pathological function of the presenilin-1 Δexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem. 1999;274:7615–7618. [PubMed]
42. Tedde A, Nacmias B, Ciantelli M, Forleo P, Cellini E, Bagnoli S, Piccini C, Caffarra P, Ghidoni E, Paganini M, Bracco L, Sorbi S. Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. Arch Neurol. 2003;60:1541–1544. [PubMed]
43. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754–760. [PubMed]
44. Katz BA, Kossiakoff A. The crystallographically determined structures of atypical strained disulfides engineered into subtilisin. J Biol Chem. 1986;261:15480–15485. [PubMed]
45. Kornilova AY, Das C, Wolfe MS. Differential Effects of Inhibitors on the gamma-Secretase Complex. Mechanistic Implications. J Biol Chem. 2003;278:16470–16473. [PubMed]
46. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. The open pore conformation of potassium channels. Nature. 2002;417:523–526. [PubMed]